Logo image of BNR

BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Price, Quote, News and Overview

NASDAQ:BNR - Nasdaq - US12233L2060 - ADR - Currency: USD

3.17  +0.11 (+3.59%)

BNR Quote, Performance and Key Statistics

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (5/29/2025, 4:30:02 PM)

3.17

+0.11 (+3.59%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High7.9
52 Week Low2.18
Market Cap32.52M
Shares10.26M
Float6.47M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-12 2020-06-12


BNR short term performance overview.The bars show the price performance of BNR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

BNR long term performance overview.The bars show the price performance of BNR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BNR is 3.17 USD. In the past month the price increased by 8.56%. In the past year, price decreased by -55.66%.

BURNING ROCK BIOTECH LTD-ADR / BNR Daily stock chart

BNR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 327.88B
AMGN AMGEN INC 13.66 152.46B
GILD GILEAD SCIENCES INC 14.36 138.21B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.81B
REGN REGENERON PHARMACEUTICALS 13.66 65.36B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.19B
ARGX ARGENX SE - ADR 98.97 35.47B
ONC BEIGENE LTD-ADR 6.32 26.67B
BNTX BIONTECH SE-ADR N/A 24.10B
NTRA NATERA INC N/A 21.58B
SMMT SUMMIT THERAPEUTICS INC N/A 19.47B
BIIB BIOGEN INC 8.39 19.45B

About BNR

Company Profile

BNR logo image Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

Company Info

BURNING ROCK BIOTECH LTD-ADR

No. 5 Xingdao Ring Road North, International Bio Island

Guangzhou GUANGDONG 510005 CN

CEO: Yusheng Han

Employees: 786

BNR Company Website

BNR Investor Relations

Phone: 8618501641666

BURNING ROCK BIOTECH LTD-ADR / BNR FAQ

What is the stock price of BURNING ROCK BIOTECH LTD-ADR today?

The current stock price of BNR is 3.17 USD. The price increased by 3.59% in the last trading session.


What is the ticker symbol for BURNING ROCK BIOTECH LTD-ADR stock?

The exchange symbol of BURNING ROCK BIOTECH LTD-ADR is BNR and it is listed on the Nasdaq exchange.


On which exchange is BNR stock listed?

BNR stock is listed on the Nasdaq exchange.


What is BURNING ROCK BIOTECH LTD-ADR worth?

BURNING ROCK BIOTECH LTD-ADR (BNR) has a market capitalization of 32.52M USD. This makes BNR a Nano Cap stock.


How many employees does BURNING ROCK BIOTECH LTD-ADR have?

BURNING ROCK BIOTECH LTD-ADR (BNR) currently has 786 employees.


What are the support and resistance levels for BURNING ROCK BIOTECH LTD-ADR (BNR) stock?

BURNING ROCK BIOTECH LTD-ADR (BNR) has a support level at 3.05 and a resistance level at 3.26. Check the full technical report for a detailed analysis of BNR support and resistance levels.


Is BURNING ROCK BIOTECH LTD-ADR (BNR) expected to grow?

The Revenue of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to grow by 48.35% in the next year. Check the estimates tab for more information on the BNR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BURNING ROCK BIOTECH LTD-ADR (BNR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BURNING ROCK BIOTECH LTD-ADR (BNR) stock pay dividends?

BNR does not pay a dividend.


What is the Price/Earnings (PE) ratio of BURNING ROCK BIOTECH LTD-ADR (BNR)?

BURNING ROCK BIOTECH LTD-ADR (BNR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.72).


What is the Short Interest ratio of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?

The outstanding short interest for BURNING ROCK BIOTECH LTD-ADR (BNR) is 0.63% of its float. Check the ownership tab for more information on the BNR short interest.


BNR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BNR. When comparing the yearly performance of all stocks, BNR is a bad performer in the overall market: 95.54% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BNR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BNR. BNR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BNR Financial Highlights

Over the last trailing twelve months BNR reported a non-GAAP Earnings per Share(EPS) of -4.72. The EPS increased by 94.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.16%
ROE -59.65%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%95.01%
Sales Q2Q%4.08%
EPS 1Y (TTM)94.71%
Revenue 1Y (TTM)-4.02%

BNR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to BNR. The Buy consensus is the average rating of analysts ratings from 5 analysts.

For the next year, analysts expect an EPS growth of -277.41% and a revenue growth 48.35% for BNR


Ownership
Inst Owners42.4%
Ins OwnersN/A
Short Float %0.63%
Short Ratio1.34
Analysts
Analysts80
Price TargetN/A
EPS Next Y-277.41%
Revenue Next Year48.35%